UK’s GW Pharma launches cannabis drug in Canada

	Tweet

GW Pharmaceuticals Plc’s pioneering cannabis-based medicine has been launched in Canada, the British firm said on Monday.

GW said its Sativex medicine was now available by prescription in Canada to treat pain in adults with multiple sclerosis.

GW’s shares plunged earlier this month when the firm lost an appeal with UK regulators, meaning it will have to produce more data on Sativex before it is considered for approval in Britain. 

RELATED STORIES:
Australia cigarette packs to show graphic photos   Smoking and alcohol - a mutually destructive combo   Britain warns of contraband cigarettes danger   British government criticized over smoking report   Cigarettes, Not Swedish Snuff Linked to Increased Risk of MS   Extreme negative anti-smoking ads can backfire, MU experts find   Smoking interferes with thinking and memory in recovering alcoholics   US tobacco bill puts focus on menthol cigarettes   Adolescent Girls on Diets More Apt to Become Smokers   Cannabis and adolescence   Current Smokers Cost Medicaid Nearly $10 Billion   Chemicals in Cigarette Smoke, Auto Exhaust and French Fries Accelerate the Development of Alzheimer’s Disease

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]